Fate Therapeutics Inc (NASDAQ: FATE) has experienced a decline in its stock price by -8.06 compared to its previous closing price of 4.22. However, the company has seen a fall of -1.77% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-06 that Fate Therapeutics (FATE) gains 86.4% on encouraging pipeline progress of its cellular immunotherapies for cancer.
Is It Worth Investing in Fate Therapeutics Inc (NASDAQ: FATE) Right Now?
Additionally, the 36-month beta value for FATE is 1.94. There are mixed opinions on the stock, with 3 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for FATE is 99.88M and currently, short sellers hold a 18.94% ratio of that float. The average trading volume of FATE on May 08, 2024 was 2.61M shares.
FATE’s Market Performance
The stock of Fate Therapeutics Inc (FATE) has seen a -1.77% decrease in the past week, with a -42.18% drop in the past month, and a -32.40% fall in the past quarter. The volatility ratio for the week is 9.56%, and the volatility levels for the past 30 days are at 8.19% for FATE. The simple moving average for the last 20 days is -19.69% for FATE’s stock, with a simple moving average of -4.34% for the last 200 days.
Analysts’ Opinion of FATE
Many brokerage firms have already submitted their reports for FATE stocks, with Wells Fargo repeating the rating for FATE by listing it as a “Equal Weight.” The predicted price for FATE in the upcoming period, according to Wells Fargo is $6 based on the research report published on March 27, 2023 of the previous year 2023.
H.C. Wainwright, on the other hand, stated in their research note that they expect to see FATE reach a price target of $7, previously predicting the price at $115. The rating they have provided for FATE stocks is “Neutral” according to the report published on January 24th, 2023.
Wedbush gave a rating of “Neutral” to FATE, setting the target price at $7 in the report published on January 06th of the previous year.
FATE Trading at -38.37% from the 50-Day Moving Average
After a stumble in the market that brought FATE to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -56.06% of loss for the given period.
Volatility was left at 8.19%, however, over the last 30 days, the volatility rate increased by 9.56%, as shares sank -42.60% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -44.17% lower at present.
During the last 5 trading sessions, FATE fell by -1.77%, which changed the moving average for the period of 200-days by -13.00% in comparison to the 20-day moving average, which settled at $4.69. In addition, Fate Therapeutics Inc saw 3.74% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at FATE starting from Dulac Edward J III, who sale 2,447 shares at the price of $7.77 back on Mar 04 ’24. After this action, Dulac Edward J III now owns 101,479 shares of Fate Therapeutics Inc, valued at $19,013 using the latest closing price.
Dulac Edward J III, the Chief Financial Officer of Fate Therapeutics Inc, sale 1,849 shares at $5.00 during a trade that took place back on Jan 29 ’24, which means that Dulac Edward J III is holding 103,926 shares at $9,245 based on the most recent closing price.
Stock Fundamentals for FATE
Current profitability levels for the company are sitting at:
- -3.0 for the present operating margin
- 0.71 for the gross margin
The net margin for Fate Therapeutics Inc stands at -2.38. The total capital return value is set at -0.41. Equity return is now at value -37.76, with -26.56 for asset returns.
Based on Fate Therapeutics Inc (FATE), the company’s capital structure generated 0.22 points at debt to capital in total, while cash flow to debt ratio is standing at -1.28.
Currently, EBITDA for the company is -159.33 million with net debt to EBITDA at -0.35. When we switch over and look at the enterprise to sales, we see a ratio of 7.92. The receivables turnover for the company is 23.31for trailing twelve months and the total asset turnover is 0.13. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.48.
Conclusion
In conclusion, Fate Therapeutics Inc (FATE) has seen bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
